Ebalzotan

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ebalzotan
Ebalzotan.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C19H30N2O2
Molar mass 318.45 g/mol
3D model (JSmol)

Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]

See also[edit]

References[edit]

  1. ^ a b Tamim Braish; Gadamasetti, Kumar G. (2008). Process chemistry in the pharmaceutical industry, volume 2 challenges in an ever changing climate. Boca Raton: CRC Press. ISBN 0-8493-9051-6. 
  2. ^ a b Weaver, Donald F.; Nogrady, Thomas; Nogrady, Th (2005). Medicinal chemistry a molecular and biochemical approach. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-510455-2.